{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:47:47Z","timestamp":1790347667723,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005363","name":"Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["UBACyT 20020170100283BA"],"award-info":[{"award-number":["UBACyT 20020170100283BA"]}],"id":[{"id":"10.13039\/501100005363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-2019-3717-2633"],"award-info":[{"award-number":["PICT-2019-3717-2633"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10072-024-07889-8","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T03:24:05Z","timestamp":1734319445000},"page":"1827-1832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in myasthenia gravis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9147-496X","authenticated-orcid":false,"given":"Florencia","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2657-788X","authenticated-orcid":false,"given":"Mariano E.","family":"Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Cialdella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-216X","authenticated-orcid":false,"given":"Mariela L.","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"7889_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","volume":"2","author":"A Vincent","year":"2002","unstructured":"Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797\u2013804. https:\/\/doi.org\/10.1038\/nri916","journal-title":"Nat Rev Immunol"},{"key":"7889_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:1\u201319. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"7889_CR3","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1021\/acschemneuro.9b00041","volume":"10","author":"ML Paz","year":"2019","unstructured":"Paz ML, Barrantes FJ (2019) Autoimmune attack of the neuromuscular junction in myasthenia gravis: nicotinic acetylcholine receptors and other targets. ACS Chem Neurosci 10:2186\u20132194. https:\/\/doi.org\/10.1021\/acschemneuro.9b00041","journal-title":"ACS Chem Neurosci"},{"key":"7889_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368. https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"key":"7889_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor\u2013related protein 4 in myasthenia gravis. Ann Neurol 69:418\u2013422. https:\/\/doi.org\/10.1002\/ana.22312","journal-title":"Ann Neurol"},{"key":"7889_CR6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D (2001) Myasthenia gravis. The Lancet 357:2122\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(00)05186-2","journal-title":"The Lancet"},{"key":"7889_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","volume":"49","author":"F Romi","year":"2017","unstructured":"Romi F, Hong Y, Gilhus NE (2017) Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol 49:9\u201313. https:\/\/doi.org\/10.1016\/j.coi.2017.07.006","journal-title":"Curr Opin Immunol"},{"key":"7889_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","volume":"4","author":"LL Kusner","year":"2008","unstructured":"Kusner LL, Kaminski HJ, Soltys J (2008) Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol 4:43\u201352. https:\/\/doi.org\/10.1586\/1744666X.4.1.43","journal-title":"Expert Rev Clin Immunol"},{"key":"7889_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","volume":"146","author":"J Chamberlain-Banoub","year":"2006","unstructured":"Chamberlain-Banoub J, Neal JW, Mizuno M et al (2006) Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 146:278\u2013286. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03198.x","journal-title":"Clin Exp Immunol"},{"key":"7889_CR10","doi-asserted-by":"publisher","unstructured":"Aguirre F, Manin A, Fernandez VC et al (2020) C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis. Ther Adv Neurol Disord 13:1\u20138. https:\/\/doi.org\/10.1177\/1756286420935697","DOI":"10.1177\/1756286420935697"},{"key":"7889_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR et al (2014) Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 49:483\u2013486. https:\/\/doi.org\/10.1002\/mus.23944","journal-title":"Muscle Nerve"},{"key":"7889_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","volume":"83","author":"T Masuda","year":"2012","unstructured":"Masuda T, Motomura M, Utsugisawa K et al (2012) Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry 83:935\u2013940. https:\/\/doi.org\/10.1136\/jnnp-2012-302705","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7889_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0114060","volume":"9","author":"AT Heldal","year":"2014","unstructured":"Heldal AT, Eide GE, Romi F et al (2014) Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS ONE 9:1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0114060","journal-title":"PLoS ONE"},{"key":"7889_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ana.410100506","volume":"10","author":"RSA Tindall","year":"1981","unstructured":"Tindall RSA (1981) Humoral immunity in myasthenia gravis: Biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 10:437\u2013447. https:\/\/doi.org\/10.1002\/ana.410100506","journal-title":"Ann Neurol"},{"key":"7889_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10072-015-2236-8","volume":"36","author":"SY Kang","year":"2015","unstructured":"Kang SY, Oh JH, Song SK et al (2015) Both binding and blocking antibodies correlate with disease severity in myasthenia gravis. Neurol Sci 36:1167\u20131171. https:\/\/doi.org\/10.1007\/s10072-015-2236-8","journal-title":"Neurol Sci"},{"key":"7889_CR16","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","volume":"33","author":"UA Besinger","year":"1983","unstructured":"Besinger UA, Toyka KV, H\u00f6mberg M et al (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316\u20131316. https:\/\/doi.org\/10.1212\/WNL.33.10.1316","journal-title":"Neurology"},{"key":"7889_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","volume":"505","author":"FM Howard","year":"1987","unstructured":"Howard FM, Lennon VA, Finley J et al (1987) Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis a. Ann N Y Acad Sci 505:526\u2013538. https:\/\/doi.org\/10.1111\/j.1749-6632.1987.tb51321.x","journal-title":"Ann N Y Acad Sci"},{"key":"7889_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1212\/WNL.39.8.1057","volume":"39","author":"AR Pachner","year":"1989","unstructured":"Pachner AR (1989) Anti-acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of TE671 cells. Neurology 39:1057\u20131057. https:\/\/doi.org\/10.1212\/WNL.39.8.1057","journal-title":"Neurology"},{"key":"7889_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R et al (2023) Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol 146:319\u2013336. https:\/\/doi.org\/10.1007\/s00401-023-02603-y","journal-title":"Acta Neuropathol"},{"key":"7889_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ana.410370513","volume":"37","author":"JJ Plomp","year":"1995","unstructured":"Plomp JJ, van Kempen GTH, de Baets MBH et al (1995) Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 37:627\u2013636. https:\/\/doi.org\/10.1002\/ana.410370513","journal-title":"Ann Neurol"},{"key":"7889_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/nyas.13472","volume":"1412","author":"X Wang","year":"2018","unstructured":"Wang X, Rich MM (2018) Homeostatic synaptic plasticity at the neuromuscular junction in myasthenia gravis. Ann N Y Acad Sci 1412:170\u2013177. https:\/\/doi.org\/10.1111\/nyas.13472","journal-title":"Ann N Y Acad Sci"},{"key":"7889_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jnnp-2019-322640","volume":"91","author":"H Cetin","year":"2020","unstructured":"Cetin H, Webster R, Liu WW et al (2020) Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs. J Neurol Neurosurg Psychiatry 91:526\u2013532. https:\/\/doi.org\/10.1136\/jnnp-2019-322640","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7889_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.410430408","volume":"43","author":"J Bufler","year":"1998","unstructured":"Bufler J, Pitz R, Czep M et al (1998) Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 43:458\u2013464. https:\/\/doi.org\/10.1002\/ana.410430408","journal-title":"Ann Neurol"},{"key":"7889_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.54.2.474","volume":"54","author":"K Jahn","year":"2000","unstructured":"Jahn K, Franke C, Bufler J (2000) Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology 54:474\u2013474. https:\/\/doi.org\/10.1212\/WNL.54.2.474","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07889-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07889-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07889-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:47:10Z","timestamp":1742320030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07889-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7889"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07889-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Bioethics Committee of the Dr. Jose Mar\u0131a Ramos Mej\u0131a Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}